{"id":"NCT03353740","sponsor":"Thomas Hope","briefTitle":"Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence","officialTitle":"Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-20","primaryCompletion":"2020-09-01","completion":"2020-09-01","firstPosted":"2017-11-27","resultsPosted":"2021-10-21","lastUpdate":"2021-10-21"},"enrollment":346,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Ga-68 labeled PSMA-11 PET","otherNames":["Ga-68 labeled DKFZ-PSMA-11","Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED-CC","Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC","Ga-68 labeled HBED-CC PSMA"]}],"arms":[{"label":"Ga-68 labeled PSMA-11 PET","type":"EXPERIMENTAL"}],"summary":"The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.","primaryOutcome":{"measure":"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up","timeFrame":"1 Day","effectByArm":[],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["32808077","30920593"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":346},"commonTop":[]}}